Indications & Uses
Tazofort is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Piperacillin and tazobactam should be given by intravenous infusion over 30 minutes. Adult Patients: The usual total daily dose of piperacillin and tazobactam for adults is 3.375 g every six hours, totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam) per day. Treatment is usually continued for 7 to 10 days. Nosocomial Pneumonia: Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam) per day. The recommended duration of treatment for nosocomial pneumonia is 7 to 14 days. Treatment with the aminoglycoside should be continued in patients from whom Pseudomonas aeruginosa is isolated. Pediatric Patients: For children with appendicitis and/or peritonitis who are 9 months of age or older, weigh up to 40 kg, and have normal renal function, the recommended dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours. For pediatric patients between 2 months and 9 months of age, the recommended dosage, based on pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours. Pediatric patients weighing over 40 kg with normal renal function should receive the adult dose. How to adjust the dosage in pediatric patients with renal impairment has not yet been determined.
Side Effects
Adverse events mainly affecting the skin, including rash, pruritus and purpura; the gastrointestinal system, including diarrhea, constipation, nausea, vomiting, dyspepsia and abdominal pain; general disorders and administration site conditions, including fever, injection site reaction (≤1%) and rigors (≤1%); immune system disorders, including hypersensitivity reactions and anaphylactic/anaphylactoid reactions, including shock (≤1%); infections such as candidiasis and pseudomembranous colitis (≤1%); metabolism and nutrition disorders such as hypoglycemia (≤1%); musculoskeletal and connective tissue disorders such as myalgia and arthralgia (≤1%); psychiatric disorders such as insomnia; and vascular disorders such as phlebitis, thrombophlebitis (≤1%), hypotension (≤1%) and flushing (≤1%). Respiratory, thoracic and mediastinal disorders may include epistaxis (≤1%).
Cautions & Contraindications
Warnings & Precautions
Serious hypersensitivity reactions (anaphylactic/anaphylactoid) reactions have been reported in patients receiving Piperacillin and tazobactam. Discontinue Piperacillin and tazobactam if a reaction occurs.Piperacillin and tazobactam may cause severe cutaneous adverse reactions, such as Stevens- Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. Discontinue Piperacillin and tazobactam for progressive rashes.Hematological effects (including bleeding, leukopenia and neutropenia) have occurred. Monitor hematologic tests during prolonged therapy.Nephrotoxicity in critically ill patients has been observed; the use of Piperacillin and tazobactam was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients. Based on this study, alternative treatment options should be considered in the critically ill population. If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with Piperacillin and tazobactam.Clostridium difficile associated diarrhea: Evaluate patients if diarrhea occurs.
Contraindications
Piperacillin + tazobactam should not be used in patients who have previously had an allergic reaction to any penicillin, cephalosporin, or β-lactamase inhibitor.